f351
Generic: hydronidone·Code: F351
f351: developed by 1 company · 1 FDA decision. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| GYRE THERAPEUTICS, INC. (GYRE) | Preclinical |
FDA Decisions
FDA_MeetingThe company completed a Pre-New Drug Application communication meeting with the Center for Drug Evaluation of China's NMPA regarding its anti-fibrotic therapy.(GYRE)
Frequently asked questions
Who is developing f351?
f351 is being developed by GYRE THERAPEUTICS, INC..
What is f351's latest FDA decision?
The most recent tracked FDA decision for f351 is FDA_Meeting for The company completed a Pre-New Drug Application communication meeting with the Center for Drug Evaluation of China's NMPA regarding its anti-fibrotic therapy., dated January 5, 2026.
Get deeper analysis on f351
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis